Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers
- PMID: 14633152
- DOI: 10.1046/j.1523-1755.2003.00328.x
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers
Abstract
Background: Hyperphosphatemia is a risk factor for the development of several different complications of chronic kidney disease (CKD), including secondary hyperparathyroidism and cardiovascular complications, due to the formation of calcium-phosphate deposits. Fibroblast growth factor-23 (FGF-23) is a recently discovered protein that is mutated in autosomal-dominant hypophosphatemic rickets, an inherited phosphate wasting disorder, and it may represent a novel hormonal regulator of phosphate homeostasis. We therefore hypothesized that FGF-23 levels may be altered in hyperphosphatemia associated with renal failure and that its concentration changes in response to different levels of phosphate intake.
Methods: Using a two-site enzyme-linked immunosorbent assay (ELISA) detecting the C-terminal portion of FGF-23, serum concentration was measured in 20 patients with different stages of renal failure (creatinine range 155 to 724 micromol/L), in 33 patients with end-stage renal disease (ESRD) on dialysis treatment, and in 30 patients with functioning renal grafts. Furthermore, six healthy males were given oral phosphate binders in combination with low dietary phosphate intake for 2 days followed by 3 days of repletion with inorganic phosphate. FGF-23 levels were determined at multiple time points.
Results: FGF-23 serum levels were significantly elevated in CKD with a strong correlation between serum creatinine and FGF-23 concentration. Independent correlations were also seen between FGF-23 and phosphate, calcium, parathyroid hormone (PTH), and 1,25(OH)2D3. No changes in serum FGF-23 levels were observed in volunteers following ingestion of oral phosphate binders/low dietary phosphate intake, which led to a decline in phosphate excretion or during the subsequent repletion with inorganic phosphate through oral phosphate and a normal diet.
Conclusion: Circulating FGF-23 was significantly elevated in patients with CKD and its concentration correlated with renal creatinine clearance. In healthy volunteers, FGF-23 levels did not change after phosphate deprivation or phosphate loading.
Similar articles
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
FGF-23 in patients with end-stage renal disease on hemodialysis.Kidney Int. 2004 May;65(5):1943-6. doi: 10.1111/j.1523-1755.2004.00604.x. Kidney Int. 2004. PMID: 15086938
-
Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.J Clin Endocrinol Metab. 2005 Mar;90(3):1519-24. doi: 10.1210/jc.2004-1039. Epub 2004 Dec 21. J Clin Endocrinol Metab. 2005. PMID: 15613425
-
Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.Adv Chronic Kidney Dis. 2011 Mar;18(2):120-31. doi: 10.1053/j.ackd.2011.02.004. Adv Chronic Kidney Dis. 2011. PMID: 21406297 Review.
-
Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.Am J Kidney Dis. 2004 Aug;44(2):250-6. doi: 10.1053/j.ajkd.2004.04.029. Am J Kidney Dis. 2004. PMID: 15264182
Cited by
-
Potential Predictors of Plasma Fibroblast Growth Factor 23 Concentrations: Cross-Sectional Analysis in the EPIC-Germany Study.PLoS One. 2015 Jul 20;10(7):e0133580. doi: 10.1371/journal.pone.0133580. eCollection 2015. PLoS One. 2015. PMID: 26193703 Free PMC article.
-
Determination of the reference interval for urinary klotho to creatinine ratio of healthy dogs.Front Vet Sci. 2024 Jul 23;11:1423390. doi: 10.3389/fvets.2024.1423390. eCollection 2024. Front Vet Sci. 2024. PMID: 39113723 Free PMC article.
-
FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.Am J Physiol Endocrinol Metab. 2013 Apr 15;304(8):E863-73. doi: 10.1152/ajpendo.00596.2012. Epub 2013 Feb 26. Am J Physiol Endocrinol Metab. 2013. PMID: 23443925 Free PMC article.
-
Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism.J Am Soc Nephrol. 2012 Oct;23(10):1641-51. doi: 10.1681/ASN.2012010048. Epub 2012 Aug 9. J Am Soc Nephrol. 2012. PMID: 22878961 Free PMC article.
-
Osteoglycin as a Potential Biomarker of Mild Kidney Function Impairment in Type 2 Diabetes Patients.J Clin Med. 2021 May 20;10(10):2209. doi: 10.3390/jcm10102209. J Clin Med. 2021. PMID: 34065223 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical